In the evolving landscape of drug discovery, the digital transformation of pathology is moving far beyond the mere convenience of remote work. Once a niche specialty, digital pathology has evolved into a powerhouse of data intelligence. Researchers are now leveraging high-resolution imagery and sophisticated artificial intelligence to “mine” archives of biological samples, effectively turning yesterday’s diagnostic reports into tomorrow’s breakthroughs. This shift is not only enhancing scientific precision but is also serving as a critical pillar in the global movement to reduce, refine, and replace animal testing in preclinical safety studies.
The Paradigm Shift: From Disposable Slides to Data Assets
For decades, the standard lifecycle of a pathology slide was linear and finite: a pathologist examined a tissue sample, documented the findings, and the glass slide was relegated to long-term storage, effectively becoming a “dead” asset.
“Before, the pathology endpoint was just a report,” explains Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories. “Now, you have the digitized slide, which is essentially a treasure trove of pixels.”
This transition from physical glass to digital data allows researchers to pair imaging with molecular measurements and historical metadata. By training machine learning models to identify patterns associated with specific biological changes, scientists can now extract insights from slides that were initially processed for entirely different purposes. In essence, a single digital slide can now answer multiple scientific questions without requiring a new animal study.
Chronology: The Evolution of Digital Pathology
The rapid adoption of digital pathology can be traced through a series of catalytic events:
- 2020–2021: The Pandemic Catalyst: Faced with lockdowns and the inability to physically access microscopes, pathologists were forced to adopt digital slide-scanning technologies to continue their work. This period broke the cultural barrier, normalizing remote diagnostic workflows.
- 2022: FDA Modernization Act 2.0: This landmark legislation signaled a major regulatory shift, permitting non-animal methods to support applications for human clinical trials. It created a legal framework that encouraged the industry to look beyond traditional animal models.
- 2024: Strategic Industry Shifts: In April 2024, Charles River Laboratories launched its “Alternative Methods Advancement Project,” a formal initiative aimed at integrating New Approach Methodologies (NAMs) into the standard drug discovery pipeline.
- 2025: Regulatory Standardization: The OECD issued updated guidance on sample collection for “omics” analysis, emphasizing the role of preserved tissue in molecular investigations and establishing best practices for ensuring data quality.
- 2026: The New Normal: The FDA released comprehensive updates in September 2026, further refining its roadmap to make non-animal methodologies the default for preclinical safety assessments, with a multi-year goal to relegate animal testing to the exception rather than the norm.
Supporting Data: Leveraging Virtual Controls and Archived Samples
The industry’s push toward reducing animal usage is supported by two primary strategies: the implementation of virtual control groups and the molecular interrogation of archived FFPE (Formalin-Fixed, Paraffin-Embedded) blocks.
The Power of Virtual Control Groups
In traditional toxicology, control groups—animals that do not receive the test drug—comprise a significant portion of study subjects. By establishing rigorous, matched historical data, companies like Charles River are developing “virtual control groups.” By comparing current experimental results against highly reliable historical baselines, researchers can significantly reduce the number of animals required for each study without compromising the integrity of the safety data.
Mining the Archive
FFPE blocks are the workhorses of pathology. While researchers historically looked for morphological changes under a microscope, modern molecular techniques allow for the analysis of gene expression and protein activity within these stored blocks.
“You have the option to use FFPE material that was already part of a lot of studies for additional information,” says Dr. Zuraw. “You don’t lose the context of the study. You can extract more from the same animals, from the same blocks, without running a new experiment.”
This approach ensures that the valuable biological context—such as the dose administered and the original observations—remains intact, allowing for deep, retrospective research that was previously impossible.
Implications for the Future of Drug Discovery
The implications of this digital evolution are profound, touching on ethics, efficiency, and the speed of innovation.
The Rise of Virtual Staining
Perhaps one of the most exciting frontiers is "virtual staining." By using software to generate the appearance of a stain on an unstained tissue section, labs can theoretically skip the physical staining process entirely. This reduces the consumption of reagents, decreases the potential for manual error, and speeds up the time it takes to get results from a tissue sample.
A “Snowball Effect” for Adoption
For this to reach its full potential, Dr. Zuraw notes the importance of a “snowball effect.” As more laboratories adopt digital systems to share and store data, the sheer volume of accessible information increases. This creates a feedback loop: the more data that is digitized, the more useful AI models become; as AI models become more accurate, the demand for digital pathology grows, driving further investment in infrastructure.
Regulatory Transformation
The shift is also forcing a transformation in how regulatory agencies interact with drug developers. As the FDA moves toward a model where NAMs are the default, the burden of proof is shifting to companies to demonstrate that their digital methods provide results that are equivalent to, or better than, traditional animal models. Early adopters in the field are currently acting as pioneers, troubleshooting these methods and establishing the precedents that will allow others to transition seamlessly.
Challenges and the Path Ahead
Despite the momentum, the transition is not without its hurdles. The move from glass to digital requires significant investment in hardware, data storage, and cybersecurity. Furthermore, there is the challenge of "standardization." For historical data to be used as a virtual control, the conditions under which that data was originally collected must be meticulously documented and comparable.
However, the consensus within the scientific community is that these challenges are outweighed by the long-term benefits. The ability to “re-interrogate” past studies means that as our understanding of disease biology evolves, we don’t have to start from scratch. We can simply look back at what we already know through a more powerful, digital lens.
Conclusion
The digital transformation of pathology represents a historic shift in how we approach the ethics and science of drug discovery. By unlocking the potential of archived tissue and integrating sophisticated data analytics, the scientific community is moving toward a future where the necessity of animal models is drastically minimized.
As the industry continues to refine these New Approach Methodologies, the ultimate winner will be the pace of pharmaceutical innovation. By extracting more knowledge from the samples we already have, we are not just saving animals; we are optimizing the entire research lifecycle, ensuring that every piece of biological data is used to its fullest potential in the quest to develop safer, more effective treatments for human disease. The era of the "one-way street" for tissue samples is over; in its place is a dynamic, data-driven cycle of discovery that promises to reshape the future of medicine.
About the Author
